Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

OSI Pharmaceuticals25 enrolled

Overview

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

OSI-7904LDRUG

CisplatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * Advanced and/or metastatic solid tumor for which no effective therapy is available * ECOG performance status 0-2 * Adequate bone marrow, hepatic and renal function Exclusion Criteria: * Patients with active or uncontrolled infections * Neurotoxicity \>= Grade 2 * Symptomatic brain metastases which are not stable

Locations (2)

Vanderbilt Universtiy Medical Center

Nashville, Tennessee, United States

Institute for Drug DevelopmentCancer Therapy & Research Center

San Antonio, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.